Matt Kalaycio, MD, a phenomenal leukemia specialist at the Cleveland Clinic, simplifies initial therapy and monitoring decisions for CML, financial implications for patients treated with TKIs, and treatment choices dictated by payers for patients with specific characteristics.
I recall the first presentation I have ever heard about Gleevec at a plenary session at ASH. Amazing how much we have advanced since and Matt summarizes everything for us.
This podcast is produced by the Journal of Clinical Pathways.
Dr. Pedro Barata, Director of the Clinical Genitourinary Medical Oncology Research Program at UH Seidman Cancer Center, provides an exclusive round-up of the most groundbreaking and practice-changing research unveiled at the ASCO GU 2024 meeting. With expertise and insight, he delves into pivotal studies such as CheckMate 914 Part B and KEYNOTE-564, exploring their implications
Dr. LaBelle elucidates the complexities of sickle cell disease, unraveling the devastating impact it has on individuals. The episode delves into various treatments and approaches to combat this formidable disease, including bone marrow transplant and the groundbreaking use of CRISPR-Cas9 technology. LaBelle shares insights into the recent research breakthroughs, citing the remarkable research report published
n this poignant episode, USA Today investigative journalist Emily Le Coz unravels the heart-wrenching narrative of Ashleigh Anderson, a CVS pharmacist whose tragic demise serves as a cautionary tale of overwhelming stress in the workplace. Emily shares her motivations behind delving into the pervasive issue of burnout in retail pharmacy and sheds light on the
